Why is Lilly research so impotent?

Quote
Anonymous said:
Poor management. The last drug invented and launched by Lilly was Cymbalta (2003), the drug was actually first synthesized in the late 1980's. The worst disaster I think is the Biotech area under TB and his utterly incompetent managers. In 16 years these people have not come up with a single drug while burning through hundreds of millions of dollars. The AME fiasco needs to be shut down, I suspect it will fairly soon.
Click to expand...

Lilly doesn't seem to be on track to gain anything meaningful from either AME or Imclone (based on what is currently in development). JL has pushed the biotech initiative but it is yet to come close to paying off. Both JL and TB deserve a grade of F- for how they have handled things. I doubt either will be employed by LLY 2 years from now. And yes, AME will be gone soon enough as Lilly follows Pfizer in shuttering their San Diego operations.
 






Anonymous said:
Lilly doesn't seem to be on track to gain anything meaningful from either AME or Imclone (based on what is currently in development). JL has pushed the biotech initiative but it is yet to come close to paying off. Both JL and TB deserve a grade of F- for how they have handled things. I doubt either will be employed by LLY 2 years from now. And yes, AME will be gone soon enough as Lilly follows Pfizer in shuttering their San Diego operations.
Click to expand...

Oh please.. be serious. JL knows the skeletons in the closet. Like any other Haaavarrrd grad
 






Reply to #21 who hit it the nail on the head. TB is universally loathed by the other therapeutic are VP's and CSO's. No doubt AME will be flushed down the toilet soon enough and that loser along with it.
 






Anonymous said:
Reply to #21 who hit it the nail on the head. TB is universally loathed by the other therapeutic are VP's and CSO's. No doubt AME will be flushed down the toilet soon enough and that loser along with it.
Click to expand...

Don't you remember John's comments about AME and San Diego. Said he wanted to move there himself. Things could have been so different.
 












Speaking of JY, this is really a symptom of dysfunction. This was a really promising guy,
hired at entry level around 2000-2001, rose to VP in 9 years and all of a sudden ...poof...he is reallocated. Maybe he was moved up too fast, maybe he was not quite ready, but he should not have been pushed out. It makes the leadership look worse, first they can't move him up fast enough...next they can't seem to get rid of him fast enough. Any thoughts on this?
 






Anonymous said:
Speaking of JY, this is really a symptom of dysfunction. This was a really promising guy, hired at entry level around 2000-2001, rose to VP in 9 years and all of a sudden ...poof...he is reallocated. Maybe he was moved up too fast, maybe he was not quite ready, but he should not have been pushed out. It makes the leadership look worse, first they can't move him up fast enough...next they can't seem to get rid of him fast enough. Any thoughts on this?
Click to expand...

What happened to his department? Was he replaced or is that whole area undergoing changes? Who else has gotten the heave-ho?
 






Im in sales so i do not pretend to know what your world is like. From reading these posts, its clear that you seem to be working with your hands tied. Any great discovery comes with great risk. It is too bad that you are generally not encouraged to push the envelope. How are we to grow if thinking outside the box is not supported. It seems they are more concerned with wasting money than supporting innovation. The ultimate allegiance seems to be to wall street and not research. The dont seem to get that without research- we have nothing.....if any division should be encouraged to take risks it should be the research scientists. Good luck to you all
 






reply to #27

They moved the guy who used to run Avid (now a Lilly subsidiary) into JY's slot, and gave JY the heave-ho. I guess there was no room for him back in the cancer area where he came from.
 






Anonymous said:
Reply to #21 who hit it the nail on the head. TB is universally loathed by the other therapeutic are VP's and CSO's. No doubt AME will be flushed down the toilet soon enough and that loser along with it.
Click to expand...

TB = dinosaur, retired-in-place for two decades or more. Destroyed CV, then moved to his new, inscrutable and irrelevant position. He need to join GUS.
 






No kidding....the guy is a disaster. He drove the "strategic" acquisition of AME almost 10 years ago for $400 million and it is basically a West Coast country club for TB and his flunkies. Can anyone think of any drugs that have comeout of AME? ......??
 












He did get thrown overboard. You are right, he did come out of cancer but was moved over Translational Science about two years ago and was in that position until January of this year.
 






O P E N L E T T E R T O T H E A C S C O M M U N I T Y


Many of you are preparing for your trip to New Orleans for the Spring ACS meeting in April. Not only is New Orleans a great place to visit, but Jim Seiber has done a terrific job at programming a technical meeting around the theme Chemistry of Energy and Food. That is certainly an appropriate theme for the gulf region and New Orleans, and if you are able to attend this meeting, I expect you will enjoy the wonderful cuisine and entertainment in the Big Easy.

It is also time to start thinking about the Fall ACS meeting in Indianapolis, September 8 -12, 2013. Our theme for Indy is Chemistry in Motion. We are interpreting this theme quite broadly to include not only topics directly related to transportation, but also to chemistry that “drives” innovation. The technical program will include a number of division-sponsored symposia that expand the theme to a variety of topics where chemistry is the “driver” for technology, for example, materials, energy production and storage (e.g., capacitors and batteries), hydraulic fracturing, graphene, carbon dioxide capture and sequestration, catalysts, conversion of biomass, nanotechnology and may others. At least ten divisions will offer programs that deal with the theme, and all the ACS divisions will present a wide variety of chemistry symposia that are bound to teach and inspire chemists from all disciplines.

Indianapolis, of course, invokes images of Formula One racing and the most famous race track in the U.S., the Indianapolis Motor Speedway (IMS) – the Brickyard. In addition to what promises to be a top quality technical program, the Indiana ACS local section has organized a fantastic event on Sunday in coordination with the Annual Celebrate Science Indiana Event, which will include STEM-related hands-on exhibitions. There will also be multiple racing-related exhibits. Food, beverages and souvenirs will, of course, also be available. On Monday, the racing theme will continue with a thematic symposium, Chemistry of Racing, which will be held at the Conference Center and feature a talk on racing from a former IndyCar driver.

I hope you are considering participating in the technical program and meeting for Indianapolis. Now is the time to think seriously about this. The abstract submission page opened for the Indianapolis meeting on March 18, 2013. You can find the list of symposia for each division at the conference site. We look forward to seeing you in Indianapolis.

<Huh? No mention of the mothership?>
 






But not as impotent as AZ.

LONDON (Reuters) - AstraZeneca (NYSE: AZN - news) is to cut around 1,600 jobs as it overhauls research operations and consolidates drug development work in three major centres in Britain, the United States and Sweden. The move will see the end of drug development at AstraZeneca's Alderley Park facility in northwest England, for many years a hub of the group's research and development (R&D) efforts, the drug maker said on Monday.
New Chief Executive Pascal Soriot, who will present his detailed strategy plans for the group to investors on March 21, said the programme would lead to $1.4 billion (927 million pounds) in one-time restructuring charges. Annualised benefits of the overhaul are expected to reach approximately $190 million by 2016. Soriot told Reuters that future R&D would be more intently focused on three key therapy areas - cancer; cardiovascular and metabolism disorders; and respiratory and inflammatory diseases - with reduced spending on anti-infectives and neuroscience. The decision to spend less on infection, which comes at a time when health officials are warning of a lack of new drugs to fight antibiotic resistance, highlights the reluctance of drug firms to invest in an area with poor returns.
AstraZeneca also aims to step up its pace of deal-making to replenish a sparse drug pipeline and Soriot said the emphasis would be on finding promising products in the three priority areas via a series of licensing deals and acquisitions. "We can succeed and return to growth without a large deal. Our focus will be more on a string of business development initiatives and bolt-on acquisitions," he added in an interview. CAMBRIDGE HEADQUARTERS Soriot's R&D plans include a $500 million investment in a new, purpose-built facility in Cambridge, eastern England, where AstraZeneca aims to tap into an environment of world-class academic and clinical life sciences research. He also plans to move the company's global corporate headquarters to Cambridge from London by 2016. Its MedImmune unit in Gaithersburg, Maryland, will be the main centre for biotech drug research while Moelndal in Sweden will focus on traditional chemical drugs. Citigroup analyst Mark Dainty said in a research note: "The pay-off is likely to take several years to be realised but is evidence of sensible organisational change." The decision to stop drug research at Alderley Park, the company's largest R&D site, is a major blow to a region that has relied on a centre where AstraZeneca and its predecessor ICI have been discovering medicines for more than 40 years.
 












Anonymous said:
lOOnberrrg is working so hard to convert LLY's R&D into a mirror of AZ's...and he's doing it!!
Click to expand...

Drug the poor people with expensive anti-psychotics, so you don't need any R&D

A new study from the University of Maryland (UM) found that use of antipsychotic drugs from 1997 to 2006 increased 7- to 12-fold in a Medicaid population of about 500,000 children ages two to 17.

R&D? Just change the molecule or formulation for more patent life, stick the multi-billion dollar bill to Medicare. Don't you just love Bush-era capitalism?
 






Anonymous said:
No kidding....the guy is a disaster. He drove the "strategic" acquisition of AME almost 10 years ago for $400 million and it is basically a West Coast country club for TB and his flunkies. Can anyone think of any drugs that have comeout of AME? ......??
Click to expand...

There are no marketed drugs that came from AME yet. There are a few in development but none looks that promising. Both AME and Imclone are shaping up as epic failures on Lilly's part. Sales of Erbitux have remained modest and the pipeline from Imclone looks equally iffy as that originating from AME. Bottom line: biotechnology will not save LLY from itself. Yes it really is that dire a situation in the long run.

And regarding TB - Xigris - enough said. Pathetic legacy, perhaps only good when compared to the likes of SP http://www.cafepharma.com/boards/images/icons/lol.gif
 












Regarding the $6 billion acquisition of Imclone, as you said, the Erbitux revenues are modest and I suspect that unless ramucirumab pans out there is not much there in the way of new products. As far as AME 10 years later we have nothing to show for it other than a continual cash drain. For the money we have wasted we could have acquired real drugs.
By way of example, Abbott bought Humira (by acquiring Knoll for 7 billion) and now have 9 bilion dollar/year (!) drug. Amgen got Enbrel (by buying Immunex for 11 billion) which is doing about 5 billion/year now. By comparison the 400 million or so we are getting from Imclone is a puny return considering the original 6 billion dollar price tag.

Just my take
 






Top Bottom
Back
Quote